SUZHOU, China, March 26, 2026 /PRNewswire/ — Alphamab Oncology (inventory code: 9966.HK) reported monetary outcomes for the complete 12 months ended December 31, 2025 and highlighted latest enterprise progress. Key Highlights KN026 (Anbenitamab) achieved strong PFS and OS advantages in second- or third-line HER2-positive GC, with information offered as a LBA oral presentation on the 2025 ESMO Congress. The primary NDA was accepted by the NMPA and obtained precedence overview standing, adopted by profitable completion of drug registration inspection and GMP compliance inspection, and is on the verge of market launch. Affected person enrollment has been accomplished for 2 part III research in…
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a worldwide community of future-focused thinkers.
Unlock tomorrow’s tendencies immediately: learn extra, subscribe to our e-newsletter, and change into a part of the NextTech neighborhood at NextTech-news.com
